Clinical Trial Update: Influence Of Salmeterol Xinafoate/Fluticasone Propionate (50/500 µg BID) On The Course Of The Disease And Exacerbation Frequency In COPD Patients Gold Stage III And IV [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating the effect of Salmeterol Xinafoate/Fluticasone Propionate (50/500 µg BID) on disease progression and exacerbation frequency in COPD GOL…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Salmeterol xinafoate / fluticasone propionate (Salmeterol xinafoate / fluticasone propionate)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Pulmonary Disease, Chronic Obstructive | Phase 4 | Status: COMPLETED | Results posted: 2010-06-24